26 completed, 7 unknown, 1 not yet recruiting, 1 terminated. 12 Phase 2, 10 Phase 3, 7 Phase 4, 5 Not applicable, 2 Early Phase 1.
Follow Calcifediol: new trials by email Literature Review of Calcifediol trials Research Report on Calcifediol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin D Status in Young Medical Residents Calcifediol (Vitamin D) - Vitamin D Deficiency | Completed | Maimónides Biomedical Research Institute of Córdoba | 30 | 2025-10-29 | 2026-03-18 | |
| REstoration of VItamin D in Pulmonary Arterial Hypertension Calcifediol Oral Capsule, Placebo - Pulmonary Artery Hypertension, Vitamin d Deficiency | Phase 4 | Not yet recruiting | Parc de Salut Mar | 102 | 2024-07-01 | 2024-02-14 |
| Effect of Vitamin D Supplementation on Allostatic Load and Chronic Stress Along Line of Control in Azad Jammu Kashmir 25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3., Placebo - Mental Health Issue | Not applicable | Unknown | University of the Punjab | 120 | 2024-05-15 | 2024-05-14 |
| Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19). Calcifediol - SARS-CoV 2 Pneumonia | Completed | Complejo Hospitalario Universitario de Albacete | 230 | 2024-02-21 | 2025-06-05 | |
| Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis 25(OH)D3, vitamin D3 - Multiple Sclerosis, Relapsing-Remitting, Adult ALL | Phase 4 | Unknown | Tehran University of Medical Sciences | 54 | 2022-07-01 | 2022-04-22 |
| Calcifediol in the Treatment of COVID 19 Calcifediol, Best available therapy - COVID-19 | Completed | Maimónides Biomedical Research Institute of Córdoba | 728 | 2022-04-01 | 2023-04-28 | |
| Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency Calcifediol 75mcg, Calcifediol 100mcg, Calcifediol 125mcg - Vitamin D Deficiency, Vitamin D Insufficiency | Phase 2 / Phase 3 | Completed | Faes Farma, S.A. | 674 | 2020-12-23 | 2023-09-15 |
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Rayaldee, Placebo - COVID-19, Coronavirus | Phase 2 | Completed | OPKO Health, Inc. | 171 | 2020-11-02 | 2024-05-28 |
| Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome BAT + Calcifediol, BAT - SARS-CoV 2, COVID19 | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 517 | 2020-05-07 | 2023-03-03 |
| Oral 25-hydroxyvitamin D3 and COVID-19 Oral 25-Hydroxyvitamin D3 - COVID 19 | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 1500 | 2020-04-14 | 2020-06-12 |
| Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients Vitamin K2, Cholecalciferol (inactive vitamin D), Vitamin K2 and Cholecalciferol - End Stage Renal Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2019-09-01 | 2019-10-30 |
| 25-Hydroxyvitamin D Pharmacokinetic Study Calcifediol, Calciferol - Vitamin D Deficiency, Fat Malabsorption | Early Phase 1 | Completed | Boston University | 16 | 2018-10-01 | 2020-06-04 |
| Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI Calcifediol Oral Capsule, Placebo oral capsule - Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases | Phase 2 | Terminated | OPKO Health, Inc. | 44 | 2018-07-09 | 2026-04-03 |
| Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol - Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency | Phase 4 | Completed | OPKO Health, Inc. | 69 | 2018-06-08 | 2022-12-09 |
| The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture: Calcifediol (Vitamin D) - Hip Fracture, Vitamin D Deficiency | Phase 4 | Completed | Leonor Cuadra Llopart | 50 | 2018-01-01 | 2021-02-02 |
| Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury Calcifediol, Calcitriol, Placebos - Critically Ill, Acute Kidney Injury | Phase 2 | Completed | David Leaf | 150 | 2017-04-03 | 2025-09-29 |
| Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD) Calcifediol, Placebo - Asthma, Bronchial | Phase 4 | Completed | MurciaSalud | 112 | 2016-06-01 | 2017-06-16 |
| Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI) Calcifediol, Placebo - Myocardial Infarction | Phase 3 | Completed | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 109 | 2015-10-01 | 2023-10-03 |
| To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia Calcifediol, Vitamin D3, Placebo - Osteopenia/Osteoporosis | Phase 2 | Completed | dsm-firmenich Switzerland AG | 150 | 2015-09-01 | 2019-04-30 |
| Effect of vitaminD3 or 25(OH)D3 Fortified Dairy on Vitmain D Status and CVD Risk Markers vitamin D3, 25(OH) D3, Control - Hypovitaminosis D, Cardiovascular Diseases | Not applicable | Unknown | University of Reading | 18 | 2015-08-01 | 2015-09-24 |
Showing 20 of 35. Sign in to see all of them.
Vitamin D Deficiency (15) · COVID-19 (5) · Hyperparathyroidism, Secondary (5) · Kidney Failure, Chronic (5) · Hyperparathyroidism (4) · Renal Insufficiency, Chronic (4) · Cytokine Release Syndrome (3) · Kidney Diseases (3) · Parathyroid Diseases (3) · Renal Insufficiency (3) · Acute Kidney Injury (1) · Asthma (1) · Bone Diseases, Metabolic (1) · Bone Neoplasms (1) · Breast Neoplasms (1)
OPKO Health, Inc. (5) · Maimónides Biomedical Research Institute of Córdoba (3) · OPKO IP Holdings II, Inc. (2) · Tehran University of Medical Sciences (2) · dsm-firmenich Switzerland AG (2) · Ain Shams University (1) · Boston University (1) · Complejo Hospitalario Universitario de Albacete (1) · Copenhagen University Hospital, Rigshospitalet (1) · David Leaf (1) · Faes Farma, S.A. (1) · Fundación Senefro (1) · Hospital Universitario de Canarias (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · Leonor Cuadra Llopart (1)
United States (11) · Spain (10) · Switzerland (2) · Bulgaria (1) · Czechia (1) · Denmark (1) · Egypt (1) · France (1) · Iran (1) · Ireland (1) · Israel (1) · Italy (1) · Netherlands (1) · Pakistan (1) · Serbia (1)
Joel Melnick, MD (3) · Michael F Holick, PhD,MD (2) · Mohamadali Sahraian, MD (2) · Akhtar Ashfaq, MD FACP FASN (1) · Arash Shirvani, MD, PhD (1) · David E Leaf, MD, MMSc (1) · Grace McComsey, MD, FIDSA (1) · Heike Bischoff Ferrari, MD, MPH (1) · Heike Bischoff-Ferrari, Prof, Dr.PH (1) · Ish-Shalom Sofia, Professor (1) · Javier Torres, PhD (1) · John S Adams, MD (1) · Jose M Quesada, MD (1)
PMID 18192127, PMID 22552038, PMID 24838406, PMID 26747333, PMID 26890209, PMID 27496232, PMID 27496946, PMID 28327462, PMID 28931588, PMID 28994661, PMID 29126319, PMID 29931358, PMID 30053278, PMID 30914274, PMID 31093951, PMID 31138136, PMID 31518424, PMID 31959942, PMID 33154023, PMID 33757717, PMID 33809538, PMID 34008842, PMID 34029377, PMID 34343292, PMID 34508607, PMID 34845313, PMID 35506389, PMID 36385193, PMID 38178229, PMID 38772577, PMID 39218235, PMID 40205202, PMID 40573079, PMID 40924491, PMID 40952661, PMID 41531256, PMID 41942544
2017 (1), K23DK106448 (1), P50AR063020 (1), UL1TR000124 (1)